Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to eva...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2024-12-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/41297 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126060033277952 |
|---|---|
| author | Lucille Vitek Thomas Goronflot Caroline Dutriaux Antoine Deleuze Yannick Le Corre Anne-Bénédicte Duval-Modeste Cécile Fresnard Géraldine Jeudy Anouck Lamoureux Caroline Gaudy-Marqueste Delphine Legoupil Barouyr Baroudjian Jean-Matthieu L'Orphelin Lucie Peuvrel Amir Khammari Laurent Mortier Gaëlle Quereux |
| author_facet | Lucille Vitek Thomas Goronflot Caroline Dutriaux Antoine Deleuze Yannick Le Corre Anne-Bénédicte Duval-Modeste Cécile Fresnard Géraldine Jeudy Anouck Lamoureux Caroline Gaudy-Marqueste Delphine Legoupil Barouyr Baroudjian Jean-Matthieu L'Orphelin Lucie Peuvrel Amir Khammari Laurent Mortier Gaëlle Quereux |
| author_sort | Lucille Vitek |
| collection | DOAJ |
| description | Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp’s real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.
|
| format | Article |
| id | doaj-art-72668c107a5a40f4bb14dacbf647f096 |
| institution | Kabale University |
| issn | 0001-5555 1651-2057 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj-art-72668c107a5a40f4bb14dacbf647f0962024-12-13T06:42:36ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572024-12-0110410.2340/actadv.v104.41297Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre StudyLucille Vitek0Thomas Goronflot1Caroline Dutriaux2Antoine Deleuze3Yannick Le Corre4Anne-Bénédicte Duval-Modeste5Cécile Fresnard6Géraldine Jeudy7Anouck Lamoureux8Caroline Gaudy-Marqueste9Delphine Legoupil10Barouyr Baroudjian11Jean-Matthieu L'Orphelin12Lucie Peuvrel13Amir Khammari14Laurent Mortier15Gaëlle Quereux16Department of Dermatology, CHU de Nantes, Nantes, FranceNantes University, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, CIC 1413, CHU Nantes, Nantes, FranceDepartment of Dermatology, Hôpital Saint-André, Bordeaux, FranceMedical Oncology, Centre Eugène Marquis, Rennes, FranceDepartment of Dermatology, CHU d'Angers, Angers, FranceUniversité de Rouen, INSERM U519, Dermatologie, CHU de Rouen, Rouen, FranceDepartment of Dermatology, Hôpital Saint-Louis de La Rochelle, La Rochelle, FranceDepartment of Dermatology, Hôpital François-Mitterand, CHU Dijon Bourgogne, Dijon, FranceDepartment of Dermatology, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, FranceDepartment of Dermatology and Cutaneous Oncology, Aix-Marseille Université (AP-HM), Marseille, FranceDepartment of Dermatology, INNOVEO, le fonds de dotation du CHRU de Brest, Brest, FranceDepartment of Dermatology, Hôpital Saint-Louis (AP-HP), Paris, FranceDepartment of Dermatology, CHU Caen Normandie, Caen, FranceInstitut de Cancérologie de l’Ouest, Nantes, FranceNantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes, FranceDepartment of Dermatology, CHU de Lille, Lille, FranceNantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes, FranceMetastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp’s real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts. https://medicaljournalssweden.se/actadv/article/view/41297Immunotherapytebentafuspuveal melanoma |
| spellingShingle | Lucille Vitek Thomas Goronflot Caroline Dutriaux Antoine Deleuze Yannick Le Corre Anne-Bénédicte Duval-Modeste Cécile Fresnard Géraldine Jeudy Anouck Lamoureux Caroline Gaudy-Marqueste Delphine Legoupil Barouyr Baroudjian Jean-Matthieu L'Orphelin Lucie Peuvrel Amir Khammari Laurent Mortier Gaëlle Quereux Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study Acta Dermato-Venereologica Immunotherapy tebentafusp uveal melanoma |
| title | Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study |
| title_full | Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study |
| title_fullStr | Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study |
| title_full_unstemmed | Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study |
| title_short | Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study |
| title_sort | efficacy and tolerability of tebentafusp in metastatic uveal melanoma a real life retrospective multicentre study |
| topic | Immunotherapy tebentafusp uveal melanoma |
| url | https://medicaljournalssweden.se/actadv/article/view/41297 |
| work_keys_str_mv | AT lucillevitek efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT thomasgoronflot efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT carolinedutriaux efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT antoinedeleuze efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT yannicklecorre efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT annebenedicteduvalmodeste efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT cecilefresnard efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT geraldinejeudy efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT anoucklamoureux efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT carolinegaudymarqueste efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT delphinelegoupil efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT barouyrbaroudjian efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT jeanmatthieulorphelin efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT luciepeuvrel efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT amirkhammari efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT laurentmortier efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy AT gaellequereux efficacyandtolerabilityoftebentafuspinmetastaticuvealmelanomaarealliferetrospectivemulticentrestudy |